2021 FEATURED KEYNOTE PANEL:
POWER OF COLLABORATION: PARTNERING TO SAVE PATIENTS IN A PANDEMIC
Managing Director, SV Health Investors , Chair, UK Vaccine Task Force (Until January 2021)
Kate will speak about her public effort as Chair of the UK Vaccine Taskforce, the group set up by the Government’s Chief Scientific Adviser, Deputy Chief Medical Officer, Business Secretary and Health Secretary to lead UK efforts to find and manufacture a COVID-19 vaccine.
Kate will return to SV Health Investors in early 2021.
Kate won the Lifetime Achievement Award, presented by the BioIndustry Association UK in January 2017.
In her 29 years at SV Health Investors, Kate’s biotech investments have resulted in the launch of six drugs for the treatment of patients with inflammatory and autoimmune disease and cancer.
Partner, Medicxi, The scientific head of Operation Warp Speed
Moncef is a Partner at Medicxi and has been with the firm since September 2017. He is currently dedicating his attention and focus as Chief Scientist for Operation Warp Speed - the fast track programme for the development of a COVID-19 vaccine and therapeutic in the US.
Prior to Medicxi, Moncef was GlaxoSmithKline’s Head of Pharmaceutical R&D and Chairman of its Vaccines division. From this leadership role, Moncef spearheaded a profound overhaul of GSK's pharmaceutical R&D, resulting in a substantial improvement in productivity, a late-stage pipeline comprising more than 30 phase 3 programmes and a totally redesigned discovery organisation comprising 38 highly focused and accountable Discovery Performance Units.
During his career at GSK, he also headed the development of a robust vaccines pipeline, including Rotarix to prevent infantile gastroenteritis, Synflorix to prevent pneumococcal disease and Cervarix to prevent cervical cancer.